Phase 2b Open‑Label Repeat Kidney Biopsy Study

Sponsor ID
417-201-00060
Clinicaltrials.gov ID
EudraCT ID
N/A
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
N/A
Active, Not Recruiting
Sponsor ID
417-201-00060

Study Summary

Assess impact of sibeprenlimab on IgA deposition and other histological endpoints in kidney tissue at Week 52 relative to baseline

Additional Study Details

Phase
Phase 2
Study Drug
Drug: Sibeprenlimab
Type
Interventional
Masking
None (Open Label)
Estimated Enrollment
56
Additional Study Details

Inclusion and Exclusion Criteria

Inclusion Criteria

  • 1. Participants must be at least 18 years of age or older at the time of signing the informed consent/assent.
  • 2. Source-verified kidney biopsy confirmed diagnosis of IgAN.

Exclusion Criteria

  • 1. Participants who are breast-feeding and/or who have a positive pregnancy test result prior to receiving sibeprenlimab.
  • 2. Participant has coexisting chronic kidney disease, other than IgAN.

Locations

Location
Status
Location
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Status
N/A
Location
Stanford University Medical Center
Stanford, California, United States, 94305
Status
N/A
Location
Colorado Kidney Care PC
Denver, Colorado, United States, 80220
Status
N/A
Location
Massachusetts General Hospital (MGH) Harvard
Boston, Massachusetts, United States, 21144
Status
N/A
Location
Dakota Dunes
Dakota Dunes, South Dakota, United States, 57409
Status
N/A
Location
Prolato Clinical Research Center
Houston, Texas, United States, 77054
Status
N/A
Showing {first} - {last} of {total} Results